Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).

Official Title

Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD

Details

Adults age 18 years or older will be enrolled for 48 weeks and treated with 200 international units (IU), 400 IU, or 800 IU of Vitamin E or matching placebo for 24 weeks. The primary objective of the study is to determine the minimum effective dose of Vitamin E (d-alpha-tocopherol) based upon relative change in alanine aminotransferase (ALT) from baseline to 24 weeks.

Keywords

Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Vitamin E, Liver Diseases, Fatty Liver, Non-alcoholic Fatty Liver Disease, Tocopherols, alpha-Tocopherol, Vitamin E, 200 IU, Vitamin E, 400 IU, Vitamin E, 800 IU

Eligibility

Locations

  • UCSF
    San Francisco California 94143 United States
  • University of Southern California
    Los Angeles California 90089 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Links
Nonalcoholic Steatohepatitis Clinical Research Network Centers The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ID
NCT04801849
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 200 people participating
Last Updated